Sanofi — 13F Holdings & Portfolio

CIK 1121404 · latest 13F-HR filed 2026-07-28

Sanofi manages $534.0M in 13F-reported U.S. long-equity assets across 10 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are MGTX (30.86%), INBX (20.54%), NVAX (12.14%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 2 new positions, exited 1, added to 7, and trimmed 1.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Filer Information
Address
46 AVENUE DE LA GRANDE ARMEE
PARIS, I0 75017
Phone
33153774400
Filing Manager
Sanofi
Paris, I0
Signatory
Alexandra Roger
Head of Legal Corporate & Finance
Loading holdings…
AUM

$534.0M

Long-equity book

Holdings

10

Distinct positions

Period

2026-06-30

Filed 2026-07-28

Q/Q Activity

+2 / −1 / ↑7 / ↓1

vs 2026-03-31

Firm Profile & Key People
Name Title / Status Ownership Type

Top Adds (vs prior quarter)

  • MeiraGTx Holdings plc$59.2M +56.0%
  • Inhibrx Biosciences, Inc.$31.9M +40.9%
  • AnaptysBio$25.1M +82.6%
  • MapLight Therapeutics Inc.$14.1M +76.3%
  • Novavax$8.8M +15.7%
Show all 7

Top Trims

  • Immuneering Corp-$758.4K -5.3%
Show all 1

New Positions

  • Odyssey Therapeutics Inc.$37.3M
  • First Tracks Biotherapeutics Inc.$16.5M
Show all 2

Exited Positions

  • Eledon$2.5M
Show all 1
All Holdings

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 MeiraGTx Holdings plc MGTX G59665102 $164.8M 30.86% 12,197,737 SH
2 Inhibrx Biosciences, Inc. INBX 45720N103 $109.7M 20.54% 1,157,926 SH
3 Novavax NVAX 670002401 $64.8M 12.14% 6,880,481 SH
4 AnaptysBio ANAB 032724106 $55.5M 10.39% 821,917 SH
5 Odyssey Therapeutics Inc. ODTX 67613T104 $37.3M 6.98% 1,991,918 SH
6 Agomab Therapeutics NV AGMB 00860C102 $36.1M 6.76% 2,783,096 SH
7 MapLight Therapeutics Inc. MPLT 56565P103 $32.7M 6.12% 912,041 SH
8 First Tracks Biotherapeutics Inc. TRAX 337185102 $16.5M 3.10% 821,917 SH
9 Immuneering Corp IMRX 45254E107 $13.5M 2.53% 2,708,559 SH
10 Q32 Bio Inc. QTTB 746964105 $3.1M 0.58% 244,083 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-07-28 $534.0M 10 0001193125-26-318812
2026-03-31 2026-05-07 $336.0M 9 0001193125-26-210525
2025-12-31 2026-02-11 $310.4M 8 0001193125-26-045633